Portola Pharmaceuticals Announces Late-Breaker Presentation on Betrixaban at American College of Cardiology's 59th Annual Scientific Session

Wednesday, February 10, 2010 General News
Email Print This Page Comment
Font : A-A+

Oral Presentation Details

A Randomized Clinical Trial of Three Doses of a Long-Acting Oral Direct Factor Xa Inhibitor Betrixaban in Patients With Atrial Fibrillation (Presentation #3015-12)

Presenter: Dr. Michael D. Ezekowitz

Session: Late-Breaking Clinical Trials II: Cardiac Arrhythmias

Date: Monday, March 15, 8:51-9:03 a.m. ET

Location: Georgia World Congress Center, Murphy Ballroom



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook